<DOC>
	<DOCNO>NCT00251498</DOCNO>
	<brief_summary>The primary objective study determine efficacy ( response rate ) cetuximab administer combination docetaxel carboplatin treatment patient advance non-small cell lung cancer . The secondary objective study : - determine time progression overall survival patient advance NSCLC treat combination docetaxel , carboplatin , cetuximab - determine toxicity combination patient advance NSCLC . Patients stag IIIB ( pleural pericardial effusion ) IV NSCLC receive prior chemotherapy eligible participate trial . Other eligibility criterion include : ECOG PS 0-1 , normal hepatic renal function , age &gt; 18 year . Specific inclusion exclusion criterion detail Sections 4.2 4.3 .</brief_summary>
	<brief_title>Phase II Study Cetuximab Combination With Carboplatin Docetaxel Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This phase II , open label , non-randomized study patient histologically/cytologically confirm stage IIIB ( pleural pericardial effusion ) stage IV NSCLC receive prior chemotherapy . The trial evaluate efficacy safety profile combination docetaxel , carboplatin cetuximab patient advance NSCLC . Patients receive combination docetaxel carboplatin administer every 3 week plus cetuximab give weekly . A maximum four cycle chemotherapy administer patient . Patients demonstrate ongoing response ( CR/PR/SD ) end 4th cycle chemotherapy , may receive two cycle treatment . Patients continue respond ( CR/PR/SD ) six cycle therapy may receive therapy single agent cetuximab ( 250 mg/m2/week ) 1 year disease progression unacceptable toxicity , whichever occur first . Patients evaluated response , time progression , overall survival . In addition , safety profile combination assess .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically/cytologically confirm stage IIIB ( pleural pericardial effusion ) stage IV NSCLC . Age &gt; 18 year . ECOG PS 01 . No prior chemotherapy NSCLC . Measurable disease RECIST criterion . Signed IRBapproved informed consent . Adequate bone marrow function define : peripheral absolute neutrophil count ( ANC ) &gt; 1500/microL , hemoglobin &gt; 9.0 g/dL , platelet count &gt; 100,000/microL . Adequate renal function define serum creatinine level less institutional upper limit normal ( ULN ) calculated/measured creatinine clearance &gt; 65 mL/min . Adequate liver function define : serum total bilirubin &lt; ULN , serum aspartate aminotransferase ( AST ) &lt; 2.5 time ULN . Estimated life expectancy &gt; 12 week . Untreated clinically active brain metastasis . Radiotherapy within 2 week prior registration previous irradiation area measurable disease . Treatment investigational therapy within 4 week prior registration . Prior therapy agent know specifically directly target EGFR pathway . History cancer NSCLC ( except nonmelanoma skin cancer carcinoma situ cervix ) within last 5 year . Patients reproductive age group consent use effective method birth control treatment least 3 month thereafter . Patients breastfeed , positive pregnancy test exclude study . Major surgery within 3 week prior registration . Use immunosuppressive agent include systemic corticosteroid within 4 week prior registration ( corticosteroid permit physiological replacement therapy supportive care nausea emesis ) . Known history human immunodeficiency virus infection . Any comorbidity condition sufficient severity limit full compliance protocol per assessment investigator . Significant history uncontrolled cardiac disease ; i.e. , uncontrolled hypertension , unstable angina , recent myocardial infarction ( within prior 6 month ) , uncontrolled congestive heart failure , cardiomyopathy decrease ejection fraction . Concurrent serious infection . History known hypersensitivity docetaxel drug formulate polysorbate 80 . History prior severe infusion reaction monoclonal antibody . Patient &gt; Grade 2 peripheral neuropathy within 14 day prior registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Metastatic 1st line NSCLC</keyword>
</DOC>